VivoSeq
Oncology

Advanced or Metastatic Solid Tumor Malignancies

0

Pipeline Programs↗

7

Active Trials↗

4

Companies Involved↗

Advanced or Metastatic Solid Tumor Malignancies is an early-stage landscape with 0 programs across 4 companies. The most active players are Janux Therapeutics, NGM Biopharmaceuticals, Inc, Ascendis Pharma Oncology Division A/S.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Janux Therapeutics

0 programs

PreclinicalN

NGM Biopharmaceuticals, Inc

0 programs

PreclinicalA

Ascendis Pharma Oncology Division A/S

0 programs

PreclinicalN

Novita Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Recruiting4 · 57%
Active, not recruiting2 · 29%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Recruiting·JJanux Therapeutics·Phase 1·NCT05783622·130 enrolled
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Recruiting·GGigaGen, Inc.·Phase 1·NCT06258304·60 enrolled
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
Recruiting·NNational University Hospital, Singapore·Phase 1·NCT03772561·40 enrolled
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Recruiting·NNovita Pharmaceuticals, Inc.·Phase 1/2·NCT05023486·140 enrolled
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Active, not recruiting·NNGM Biopharmaceuticals, Inc·Phase 1/2·NCT04913337·179 enrolled
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Active, not recruiting·AAscendis Pharma Oncology Division A/S·Phase 1/2·NCT05081609·320 enrolled
Subjects With Advanced or Metastatic Solid Tumor Malignancies
Not yet recruiting·XXenthera, Inc.·Phase 1·NCT05474859·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)